Editing PHKG Business Opportunities (section)

== 1. Health Data Intermediary — Hospitals Sell to Clinical Trials ==

'''Concept:''' Hospital collects and curates patient data into PHKG. Pharma companies pay for access to curated, de-identified patient cohorts for clinical trial recruitment, real-world evidence generation, or post-market surveillance.

=== How It Works ===
# Hospital data (structured + unstructured) is curated into PHKG using Stamen's platform
# Patients consent to data sharing for research (GDPR-compliant, EHDS-aligned)
# Pharma/CRO searches the PHKG for cohorts matching trial inclusion criteria
# Hospital receives payment per patient enrolled or per dataset accessed
# Stamen takes a commission (platform fee) on each transaction

=== Market Context ===

'''Existing players:'''
* '''Datavant''' (US, $7B valuation 2021) — data linking and de-identification for US hospitals. Dominant in US, no EU presence.
* '''TriNetX''' (US/EU, $500M+ valuation) — federated network of 300+ organizations. Grows data, connects to pharma. Focuses on trial feasibility.
* '''LynxCare''' (Belgium, ~€50-80M) — generates real-world evidence from hospital data. Connected to Belgian hospitals.
* '''IQVIA''' (US, $35B market cap) — clinical data services. The incumbent everyone competes with.

'''What's different about PHKG approach:'''
* TriNetX and IQVIA work with structured data (ICD codes, lab values). They miss unstructured clinical notes.
* AIDAVA's NLP extracts value from discharge notes, radiology reports, specialist letters — the 80% of clinical data that's currently unstructured.
* PHKG with SNOMED CT coding enables more precise cohort matching than flat ICD-code searches.

=== Revenue Potential ===

* '''Per-patient-enrolled fee:''' €500-2,000 per patient enrolled in a clinical trial through the platform
* '''Dataset access fee:''' €10,000-50,000 per curated dataset for feasibility studies
* '''Commission rate:''' 15-30% of hospital payment

'''Realistic year 2 revenue:''' €100-300K if 1-2 hospitals are connected and 1-2 pharma/CRO partnerships exist.

=== Challenges ===

* '''Regulatory complexity:''' EHDS secondary use framework isn't finalized. GDPR consent mechanisms for data intermediaries are complex. Each country has different rules.
* '''Hospital willingness:''' Hospitals are nervous about "selling patient data." Even with consent and de-identification, there's reputational risk. The framing matters: "enabling clinical trials" not "selling data."
* '''Chicken-and-egg:''' Pharma won't pay until there's data volume. Hospitals won't invest in curation until there's pharma demand. Need a lighthouse hospital + a lighthouse pharma partner simultaneously.
* '''De-identification:''' Must be provably robust. GDPR fines for re-identification are massive. This is a trust liability.

=== Verdict ===

'''High potential, high difficulty.''' The revenue per transaction is high, but the regulatory and trust barriers are significant. Best pursued as a year 2-3 opportunity after establishing the core EHDS compliance product. Start with the hospital relationship first, add the intermediary layer later.